Figure 5. IKZF1 deletion results in increase of DNM2 expression in primary B-ALL cells.
(A) comparison of DNM2 expression in patients with or without IKZF1 deletion; (B) Effect of CK2 inhibitor (TBB) on Ikaros binding on the promoter of DNM2 in primary ALL cells; (C) Effect of CK2 inhibitor (TBB) on expression of DNM2 in primary B-ALL cells with TBB treatment for 2 days.